Arcturus Therapeutics is trading at $15.88, down -5.16%, with no clear company-specific catalyst identified.
- No September 3, 2026 announcement, earnings release, regulatory action, or analyst move was identified.
- The latest company news concerned upcoming September investor conferences, associated with the earlier rally rather than today’s decline.
- Biotechnology and major U.S. indexes were higher, so the drop does not appear explained by broad sector or market weakness; the catalyst remains unclear pending further disclosures.